Open AccessPost-COVID Pulmonary Mucormycosis: first case report from Bangladesh
Author(s) -
Farhana Afroz,
Lovely Barai,
Muhammad Abdur Rahim,
Shamima Sharmin Kanta,
Mohammad Delwar Hossain
Publication year - 2021
Publication title -
bangladesh journal of medicine
Language(s) - English
Resource type - Journals
eISSN - 2408-8366
pISSN - 1023-1986
DOI - 10.3329/bjm.v32i2.53802
Subject(s) - mucormycosis , medicine , diabetes mellitus , zygomycosis , amphotericin b , dermatology , lung , disease , intensive care medicine , antifungal , pathology , endocrinology
Mucormycosis is an invasive fungal infection caused by different saprophytic environmental fungus occurring predominantly among immunosuppressed patients. Pulmonary mucormycosis is the second most common form after rhino-cerebral mucormycosis and may accompany with other infections. Coronavirus disease 2019 (COVID-19) itself and its treatment with immunosuppressive drugs and oxygen delivery systems etc. are setting the scenes for opportunistic and co-infections with fungus and other pathogens. A middle aged Bangladeshi man, with background diabetes mellitus, hypertension, bronchial asthma and COVID-19, presented with fever, respiratory symptoms and cavitary lung lesion. Diagnostic work-up confirmed pulmonary mucormycosis and he responded with liposomal amphotericin B. To the best of our knowledge, this is the first case of post-COVID mucormycosis reported from Bangladesh.
Bangladesh J Medicine July 2021; 32(2) : 156-160